Addressing Educational Needs and Disparities in Gynecologic Cancer Care: Analysis of Insights and Impact from a Program Designed for Patients and Providers

Kevin Obholz, PhD and Krista Marcello – Clinical Care Options, LLC.

Program Link


Educational Design and Program

Smarter. Stronger. Together. Education and Resources to Optimize Clinical Outcomes in Gynecologic Cancers




Improve your ability to provide individualized, evidence-based treatment of gynecologic cancers through expert commentaries, microlearning presentations, and a gynecologic cancer care resource center.

Eloise Chapman-Davis, MD, FACOG; Kimberly J. Halla, MSN, FNP-C; Angeles Alvarez Secord, MD, MHSc; Shannon N. Westin, MD, MPH



Patient Survey → **Commentary** → **Video for Patients**



Infographic for Patients and Providers → **Microlearning Videos for Providers** → **Slides**



Learning Objectives

- Discuss with patients the underlying molecular biology of gynecologic cancers, risk factors that contribute to oncogenesis, and potential therapeutic targets
- Evaluate current and emerging practice-changing clinical data on checkpoint inhibitors and PARP inhibition as single-agent or combination therapies in cervical, endometrial, and ovarian cancer
- Plan individualized treatment strategies for patients with cervical, endometrial, and ovarian cancers that incorporate novel therapies and combination strategies
- Select maintenance therapy for patients with ovarian cancer with or without *BRCA* mutations or other homologous recombination repair deficiencies in the frontline and relapsed settings
- Evaluate available clinical data on immune checkpoint inhibitor–based therapy in endometrial cancer classified as microsatellite stable
- Describe to patients the risk factors and importance of screening, the benefits of clinical trial enrollment, and how their disease risk and clinical outcomes may differ from other patients
- Identify populations of patients who are at increased risk for poor prognosis and proactively provide education and support throughout all stages of diagnostic and treatment regimens

Program Goal

The goal of this program was to educate oncologists, oncology nurses, pharmacists, other healthcare professionals and patients about recent developments in the care of gynecologic malignancies and raise awareness of disparities in care to optimally individualize therapy for this patient population.

Supported by educational grants from AstraZeneca, GlaxoSmithKline, and Merck Sharp & Dohme Corp.

Patient Survey Results

- From July 7 to August 18, 2021, a survey was sent to women with gynecologic cancers who are active members in the Smart Patients advocacy group – **N = 89** (67% ovarian, fallopian tube, and peritoneal; 21% endometrial; 9% vulvar or vaginal; and 2% cervical)
- Survey responses were compared between non-Hispanic White patients (W) versus non-White (NW) underrepresented minority patients (Asian, Black/African American, Native American, Pacific Islander, Hispanic, or mixed race) – **86.5% were W** and **13.5% were NW**

Notable Racial Disparities in Care and Preparedness

	NW	W
Unsatisfactory discussions on the **cost of treatment**	18.2%	9.5%
Unsatisfactory discussion of **treatment options**	12.5%	4.5%
Unsatisfactory discussion of **side effects** of treatment	20.0%	0%
Discussion of *BRCA* testing and provided resources	16.7%	31.0%
No discussion of *BRCA* testing	33.3%	11.9%
Not confident in ability to work with care team to improve cancer treatment outcomes	37.5%	28.1%


General Insights From Patient Survey

Discussed genetic testing for endometrial cancer
46%

Agree or strongly agree that they were well informed about latest treatment options and clinical trials
52%

Interested in participating in clinical trials
17%

Patient Preferred Sources of information



Identifying Disparities in Gynecologic Cancer: Results and Analysis From a Patient Preference Survey

Eloise Chapman-Davis[1], Kimberly J. Halla[2], Shannon N. Westin[3], Ritu Salani[4], Jerfiz D. Constanzo[5], Timothy A. Quill[5], Kathryn Burn[6], and Angeles Alvarez Secord[7]

[1]Division of OB/GYN and Gynecologic Oncology, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY; [2]Arizona Oncology, Phoenix, AZ; [3]Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX; [4]David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA; [5]Clinical Care Options, LLC, Reston, Virginia; [6]Smart Patients, San Jose, CA; [7]Division of Gynecologic Oncology, Department of OB/GYN, Duke Cancer Institute of Duke University Health System, Durham, NC.

ASCO Poster presentation
Session Date and Time:
Saturday, June 4, 2022, 1:15 PM-4:15 PM CDT

Overall Program Metrics

Patient Learners 1020

HCP Learners 3674

Cumulative HCP Learning 4564

Slideset downloads 843

Read the commentaries 3521

Microlearning video views 1629


HCP Completers 3901

42% **Will change their practice**


266 evaluations were collected, **59.25 credits** awarded, and **>90%** indicated satisfaction across all measured domains. Extrapolated evaluation data estimates **7863 women** with gynecologic malignancies may benefit from learner participation in the program.

Educational Outcomes Analysis

Education on Racial Disparities in Care



Education on Treatment of Endometrial, Ovarian, or Cervical Cancer



Take Aways: Positive and Caution

Positive

Patients and providers can be educated effectively within a collaborative educational program.

Patient survey identifying disparities informed and impacted the HCP education.

Patients value information from their doctor the most.

Caution

Clear racial care disparities exist and represent critical ongoing educational needs.

Microlearning activities are effective in reducing learner barriers to education; however, this educational approach requires purposeful learning design to assess higher level outcomes.